tci Part B Insider - 2005 Issue 17
PHYSICIAN NOTES: CMS Will Expand Coverage Of Abarelix For Prostate Cancer
And at least one carrier will now pay for Abraxane for breast cancer If you've been providing abarelix (brand name Plenaxis) for advanced symptomatic prostate cancer, then there's good news from the Centers for Medicare and Medicaid Services. Transmittal 532 states that Medicare will expand coverage for Plenaxis to include patients for whom gonadotropin-releasing hormone (GnRH) therapy is not appropriate, who decline surgical castration, and who present with risk of neurological compromise due to metastases, ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or severe bone pain from skeletal metastases persisting on narcotic analgesia. In...
To read the full article, sign in and subscribe to tci Part B Insider.
Thank you for choosing Find-A-Code, please Sign In to remove ads.